These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 10804085

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P, Thurnher A, Hirth KP, Schilling L, Schmiedek P, Ullrich A, Menger MD.
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [Abstract] [Full Text] [Related]

  • 3. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
    Arastéh K, Hannah A.
    Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
    [Abstract] [Full Text] [Related]

  • 4. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
    Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM.
    Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
    [Abstract] [Full Text] [Related]

  • 5. VEGF receptor signaling in tumor angiogenesis.
    McMahon G.
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S, Laird D, Cherrington JM, Knox SJ.
    Radiat Res; 2002 Jan 15; 157(1):45-51. PubMed ID: 11754641
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. VEGF in brain tumors.
    Machein MR, Plate KH.
    J Neurooncol; 2000 Aug 01; 50(1-2):109-20. PubMed ID: 11245271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
    Giles FJ.
    Oncologist; 2001 Aug 01; 6 Suppl 5():32-9. PubMed ID: 11700390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.